This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.
spk08: Good morning, everyone. Welcome to ProAssurance Conference Call to discuss the company's third quarter 2020 results. These results were reported in a news release issued on November 5, 2020, and in the company's quarterly report on Form 10-Q, which was also filed on November 5, 2020. Included in these documents were cautionary statements about the significant risks, uncertainties, and other factors that are out of the company's control and could cause ProAssurance business and alter expected results. Please review those statements. Management expects to make statements on this call dealing with projections, estimates, and expectations, and explicitly identifies these as forward-looking statements within the meaning of the U.S. federal security laws and subject to applicable safe harbor protections. The content of this call is accurate only on November 6, 2020, and accept as required by law or regulation. ProAssurance will not undertake and expressly disclaim any obligation to update or alter information disclosed as part of these forward-looking statements. The management team of ProInsurance also expects to reference non-GAAP items during today's call. The company's recent news release provides a reconciliation of these non-GAAP numbers to their GAAP counterparts. Now, as I turn the call over to Mr. Ken McEwen, I would like to remind you that this call is being recorded and that there will be time for questions at the conclusion of prepared remarks. Mr. McEwen, please go ahead.
spk10: Thank you, Cole. On our call today, we have Ned Rand, President and CEO, Dana Hendricks, Chief Financial Officer, Mike Bogusky, president of our specialty property and casualty lines, and Kevin Shook, president of our workers' compensation insurance operations. Ned, there's a lot to unpack this quarter. Will you start us off?
spk03: Sure, Ken. In the third quarter, we continued to see improvement in our underlying operations as the beneficial results from our re-underwriting and restructuring efforts began to manifest as lower recurring operating expenses and improved loss experience in each of our operating segments. As one-time incurred charges related to these efforts are put behind us, we anticipate a continued favorable trajectory into the fourth quarter and into 2021. Aside from our regular operating results, we continue to learn more about the COVID-19 virus as each day passes, and we gain insight into the impact it has on our business and those of our customers. There is still much to learn about the disease, and while we have seen some favorable claims trends that are likely to result likely the result of the pandemic. We have remained cautious in recognizing these trends and our results, given the uncertainty surrounding the length and severity of the pandemic. Unfortunately, the continued market volatility caused by COVID-19 and sustained depression of our stock price has overshadowed the improvements we've made this year. I'll let Dana expand on the goodwill impairment charge we announced in yesterday's release. But I want to note that the charge has no effect on our liquidity or our statutory entities and is strictly an accounting transaction. As I mentioned in yesterday's release, I remain confident that our solid foundation and the strategic initiatives we have undertaken in the past 16 months will reward our customers, shareholders, and employees in the quarters and years to come. Dana?
spk00: Thanks, Ned. I'll start with the goodwill impairment charge recognized in the quarter as it had the largest impact to our net results. We routinely review our goodwill for potential impairment annually on October 1st. Because of continued market volatility caused by COVID-19 and the sustained depression of our stock price, we performed interim quantitative impairment tests in the third quarter. More detail is available in our filed Form 10-Q. But to summarize, we determined that while no impairment was necessary for our workers' compensation or segregated portfolio sale reinsurance reporting units, a full impairment of goodwill was indicated for the specialty P&C reporting unit. Consequently, we recorded a non-cash pre-tax goodwill impairment charge of $161.1 million, which drove a net loss in the third quarter of approximately $150 million or $2.78 per share. Importantly, we reported non-GAAP operating income of $2.6 million in the third quarter, or 5 cents per share. This excludes the effects of certain items, primarily the goodwill impairment and realized investment gains. This result reflects lower consolidated net premium earned, largely offset by lower current accident year net losses and loss adjustment expenses and lower operating expenses. Each of these components will be discussed in more detail in the segment specific portions of our call, but I think it's important to note here that they are all primarily related to the intentional restructuring and re-underwriting efforts completed over the past year. Consolidated net investment income decreased quarter over quarter to $16.9 million. This was primarily attributable to our lower allocation to equity securities coupled with lower yields on our short-term investments and corporate debt securities, given actions taken by the Federal Reserve to reduce interest rates in response to COVID-19. However, we reported $4.9 million in income from our unconsolidated subsidiaries. We invest in various LPs and LLCs, and the results of those investments are typically reported on a one-quarter lag. Accordingly, the earnings from unconsolidated subsidiaries in the current quarter represents the recovery in value of our LPs and LLCs in the second quarter of 2020. For the third quarter, our consolidated current accident year net loss ratio was 80.7%, a decrease of 1.6 percentage points quarter over quarter as the early results of our strategic underwriting efforts of the past year are beginning to manifest in our specialty PMC business. The decrease was also driven by continued favorable loss trends in our workers' compensation business. Each of our segments contributed to the $11.5 million of net favorable development we recognized in the third quarter. While lower than the year-ago period, we want to emphasize that we continue to exercise caution given the current loss environment. Our consolidated underwriting expense ratio is 30.5% in the quarter an increase of 1.8 percentage points from the year-ago period. The increase is attributable in part to lower earned premiums, but what is most important to know is that expenses in the current quarter included $3.2 million in one-time charges associated with a restructuring that resulted in 78 position eliminations through a combination of early retirements, job eliminations, reassignments, and promotions. that spanned our entire organization. This restructuring is expected to result in annual savings of approximately $7.4 million in addition to other expense saving initiatives earlier this year. The takeaway is that we have taken specific and permanent action to improve our underlying expense structure without sacrificing excellence and service. More details about the restructuring will be provided in Mike's and Kevin's remarks later. This leads us to a consolidated combined ratio of 105.3% for the third quarter. In summary, we continue to see incremental improvements in our operating results as the strategic initiatives of the past 16 months gain traction. We also anticipate expenses will normalize for the remainder of the year, furthering the gains we've seen to date. Now, I'd like to ask Mike to start our segment-specific portion of the call with the specialty P&C segment.
spk01: Thank you, Dana. The specialty P&C segment recorded a third quarter loss of $12.5 million. And while we're not satisfied with the result, it does reflect an improvement from the first and second quarters of 2020. And there are a number of encouraging aspects of the quarter, which I'll expand upon throughout my comments. Gross premiums written were $158.3 million, a decrease of 4.1% quarter over quarter, reflecting our re-underwriting efforts and healthcare professional liability and timing differences in the regular renewal cycle of 24-month policies. Notably, within our specialty book, we have reduced gross premiums written in our senior care line by almost 82% quarter over quarter. Further, the timing differences related to the 24-month policies in our standard physician line contributed $3.9 million to the reduction. We have begun the process of converting all 24-month policies to 12-month policies, which we anticipate will be completed early in the second quarter of 2021. As we've discussed in recent quarters, the re-underwriting efforts began in the third quarter last year, following the new executive hires in our healthcare professional liability underwriting operation during the previous quarter. As of the end of the third quarter of 2020, these targeted re-underwriting efforts in our HCPL business are substantially complete. We expect to benefit from the re-underwriting efforts in future quarters. We continue to focus on underwriting discipline and achievement of our long-term profit objectives, shrinking the segment's top line if necessary to improve our bottom line. In relation to these strategic underwriting efforts, Premium retention in the segment was 81% for the quarter, driven largely by a 55% retention in our specialty lines, primarily related to the senior care line of business, and includes a non-renewal of a $5.6 million policy in that line during the quarter. In our standards physician line, retention was 85%, lower by two percentage points quarter over quarter, reflecting our state-specific pricing adjustments in challenging venues and competitive market conditions. However, we continue to deliver strong premium retention results in our medical technology liability business and small business units, which were 85% and 92% respectively. The segment's lower premium retention was largely offset by renewal premium increases of 14% in specialty and 10% in standard positions. In addition to the rate increases in specialty, we have also significantly strengthened rate adequacy through our improvement of product structure, terms, and conditions. New business writings in the segment were $8.7 million in the quarter compared to $9 million a year ago. This result reflects careful risk selection, disciplined underwriting evaluation, and to a lesser degree the impact of slower submission activity due to market disruptions from COVID-19. New business writings in our medical technology liability business increased to $2 million compared to $1.3 million in the third quarter last year, as demand for pandemic-related products in the medical technology space continues to rise. The current accident year net loss ratio is 89.8% in the quarter, a 4.7% percentage point improvement from the year-ago period attributable to underwriting efforts and price strengthening. Furthermore, the current accident year net loss ratio for the first nine months of 2020, excluding the large national health care account tail policy and the $10 million COVID reserves, is approximately 6.5 percentage points lower than the full year ratio for 2019. In the quarter, we continue to observe a significant reduction in our claims frequency as compared to the same quarter in 2019, likely associated with COVID-19. However, we remain cautious in recognizing these favorable frequency trends in our current action at year reserves due to the possibility of delays and reporting and uncertainty surrounding the length and severity of the pandemic. We have not booked any additional IBNR reserves related to the pandemic during the quarter after carefully reviewing virus-related claim activity. Despite the current loss environment, we recognize net favorable prior year development of $2.9 million, of which $2.5 million is attributable to our medical technology liability line. As previously stated, we remain conservative in our views of prior year loss development as a result of the current loss environment. The specialty P&C segment reported an expense ratio of 23.8% in the quarter, essentially flat from the same quarter last year. The expense ratio reflects improvements in our expense model made during the past year offset by related one-time restructuring expenses of $1.8 million and lower net earn premium. This restructuring is expected to result in annual savings of $3.6 million in addition to other expense savings measures we've disclosed previously. As a result of our prior organizational structure enhancements, restructuring field offices and staff reductions, We anticipate quarterly run rate expense savings of $3 million in the segment or $12 million annually. We continue to build an operating model that positions us well to be successful throughout the various insurance and economic cycles. I'll conclude with a brief update on the NorCal transaction. We continue to proceed through the regulatory and integration planning process. However, once we receive preliminary regulatory approval of NorCal's proposed plan of conversion, there will be a 60 to 90-day solicitation period before the deal can close, and we anticipate the deal will close in the first quarter of 2021. The NorCal group, its employees, agents, and customers represent an exciting expansion in the standard physician marketplace. Upon completion of the transaction, Approximately 75% of our healthcare professional liability business will be written in the standard physician's line, a marketplace in which we have deep expertise and a successful history of profitability. We remain excited about the combination of the companies and our future together, and we'll continue to work together with the NorCal team to complete this transaction.
spk10: Thank you, Mike. Now I'll turn it over to Kevin Shook for comments about the results of the workers' compensation insurance and segregated portfolio sell reinsurance segments. Kevin?
spk04: Thank you, Ken. The workers' compensation insurance segment produced income of $1.5 million and a combined ratio of 97.4% for the third quarter of 2020. During the quarter, the segment booked $63 million of gross premiums written, a decrease of 10% quarter over quarter. Renewal price decreases were 3% for the quarter, representative of the continued competitive pressures in our underwriting territories despite COVID-19 and the associated economic conditions. Premium renewal retention was 86% for the 2020 quarter, compared to 84% in 2019, as we continue to see stronger premium retention each month during the pandemic. New business writings decreased quarter over quarter to $7.4 million in 2020, compared to $11.3 million in 2019. Audit premium for the third quarter of 2020 resulted in return premium to policyholders of $1.6 million compared to additional premium to the company of $1.8 million for 2019, a quarter-over-quarter decrease attributable to the economic impact of COVID-19 on policyholder payrolls. We continue to expect downward pressure in future quarters on direct and net written premium resulting from changes in payroll estimates. The calendar year net loss ratio decreased 3.2 percentage points to 62.2% in the third quarter due to a decrease in the current accident year loss ratio and higher prior year net favorable reserve development of $2 million in 2020 compared to $1.4 million in 2019. The reduction in the 2020 accident year loss ratio from 70.4% at June 30, 2020, The 69.2% at September 30, 2020 was driven by our recognition of favorable claim trends in the 2020 accident year, which I'll describe in more detail momentarily. As this reduction was fully recognized in the current quarter, the result is a third quarter current accident year loss ratio of 66.9%. The 2020 Accident Year Loss Ratio of 69.2% at September compares to 68.2% for the same period in 2019 and reflects the impact of renewal rate decreases and negative audit premium partially offset by the favorable claim trends in 2020. we've seen a 36.5% decrease in reported claim frequency during the pandemic with only $1.3 million of gross undeveloped incurred losses from the currently reported 447 COVID claims. However, management remains cautious in its evaluation of the 2020 accident-year loss ratio considering the many uncertainties surrounding the pandemic. Our claims professionals remain highly effective while working remotely, closing 47% of 2019 and prior claims during 2020, consistent with historical claim closing rates. Legislative attempts to broaden coverage for workers' compensation claims seem to have lost traction in certain states as their economies attempt to remain open and legislators focused on elections recently. We can only conjecture that a second wave or the continuation of increased reported cases may revive efforts in this regard. Turning now to expenses, The underwriting expense ratio in the quarter was 35.2% compared to 30.1% in 2019, reflecting the decrease in net premiums earned and a one-time severance charge of $923,000 related to our restructuring, which I will describe in more detail shortly. Underwriting and operating expenses were $15 million for the third quarter of 2020, essentially flat from 2019, despite the included severance charge. Turning to the segregated portfolio cell reinsurance segment, income was approximately $1.2 million for the quarter, which represents our share of the net underwriting profit and investment results of the captive programs in which we participate. Premium and loss trends in the SPC reinsurance segment were consistent with those in workers' compensation. We renewed all the alternative market programs available for renewal during the current quarter and year to date. I will wrap up by discussing recent restructuring initiatives in our workers' compensation business. COVID-19 continues to present challenges for all in the insurance marketplace. Policyholders, agency partners, and insurance carriers are conducting business in ways previously unimaginable and in some cases representing a new normal. Given these challenges, we have used the past seven months to thoroughly review the impacts of COVID and the external environment on our business, agency partners' operations, and valued customer base with the ultimate goal of enhancing our service platform to meet the ever-changing needs of the marketplace and those presented most recently. Our detailed strategic review led us to make permanent organizational adjustments to our business model. We believe these structural enhancements will allow us to grow our business profitably while strengthening our industry-leading products and services. These changes include repositioning from five regions to three for more effective and efficient management of the underwriting, risk management, and claims processes, improving the consistent application of our business model while maintaining our local service teams. We integrated small business and underwriting support functions into one unit for each with dedicated leadership, which will allow us better turnaround time on policy submissions while continuing our individual account underwriting philosophy that has been a resounding part of our success in workers' compensation. Lastly, we realigned our previously standalone captive team into our regional structure to improve accountability, and we streamlined our marketing operations to extend more agency management responsibilities to the decision makers in the underwriting process. These changes resulted in some early retirements, job eliminations, reassignments, and promotions. Striving for continuous improvement and proactive enhancements to business models are imperative as circumstances, economic trends, and changing insurance markets present themselves, and importantly, before the full operational and financial impacts are realized. Consistent with our history of evolving to meet the demands of the changing environments in which we operate, These structural enhancements will strengthen our workers' compensation business further and were applauded by our agency partners and customers. The restructuring implementation commenced September 1st and is expected to result in an annual savings of approximately $3 million in addition to other expense management measures. Ken?
spk10: Thank you, Kevin. Ned, before we get to your closing comments, I'd like to turn to the Lloyd Syndicate segment for a moment. Is there anything you want to tell us about the results from London?
spk03: Thanks, Ken, and yes. There were several notable changes to our results at Lloyd's from the prior year quarter. First, our results in the quarter were income of $3.7 million, one of the best quarters we've had since we invested in the syndicates. Our combined ratio improved 10.5 percentage points to 89.6%, as both net losses and underwriting expenses were reduced by over 20%. In addition, as a result of our reduced participation, in the third quarter, we received a return of approximately $32 million from our funds at Lloyd's. Lastly, Syndicate 6131 entered into a quota share reinsurance arrangement with an unaffiliated insurer, effectively reducing our net participation in the syndicate by half. The agreement is effective July 1, 2020. so it will not be reflected in our results until the fourth quarter of 2020 due to the quarter lag. We continue to work closely with Dale Underwriting Partners to monitor the global legislative situation pertaining to COVID. Thankfully, contractual policy language has largely held against attempts to expand coverage where no coverage was intended, particularly in the United States, and our loss estimates to date have held up. Speaking of loss estimates, given the number of natural catastrophes that occurred during the quarter, I want to note that, to date, our exposure to these events has been within our CAD expectations for the fourth quarter. Before we open the call to questions, I want to reiterate that the changes we've implemented in the quarter and over the past 16 months have been important. The changes are focused on both achieving our long-term profitability goals and enhancing the excellent products and services we provide to our customers. As a company, we have always operated with the understanding that the long cycles inherent in our industry will challenge us in troughs and reward us in peaks. Our role as a specialist is to be the absolute best possible choice for our customers, regardless of the stage of the cycle in which we find ourselves. To that end, I want to quantify our actions taken to date. You heard in Dana's remarks and throughout the call about our initiatives in each of our segments and related one-time charges. but I think it would be helpful to consolidate that information for the big picture. As a result of our strategic initiatives in 2020, we anticipate $17 million in annual expense savings. This is on top of initiatives taken in 2019 that reduced annual costs by $5 million. This brings us to estimated cumulative annual cost reductions of approximately $22 million since this leadership team was put in place over 16 months ago. which includes an overall reduction in our workforce of approximately 13%. Thus far in 2020, we've recognized a little over $5 million in one-time charges, primarily related to early retirements and job eliminations. These changes, though painful, are necessary as we create the next iteration of ProAssurance and position the company for success. As we head into the final quarter of 2020, I look forward to an exciting 2021.
spk10: Thank you, Ned. Cole, that concludes our prepared remarks. We are ready for questions.
spk08: We will now begin the question and answer session. To ask a question, you may press star then 1 on your touchtone phone. If you're using a speakerphone, please pick up your handset before pressing the keys. To withdraw your question, please press star then 2. And our first question today will come from Greg Peters with Raymond James. Please go ahead. Good morning.
spk09: So let's go back to NorCal. Everything's going on track. Since this is going to be a pretty major acquisition, can you talk about how their results have trended on a year-to-date basis and if they are deploying any re-underwriting initiatives, et cetera, just so we can have a sense of how the two organizations might look when they're combined?
spk05: Mike, do you want to take that?
spk01: Sure. Good morning, Greg. As far as the NorCal results through nine months, they're certainly executing on an underwriting plan with rate achievement and looking at their specialty book of business similar to ours. So we're pleased with that. They're certainly booking higher accident year loss ratios. I believe it's high 90s and kind of a combined ratio roughly in the kind of 120 range through 930. The other thing I'd say just overall is they're seeing the same things we are with less claims frequency in their 2020 accident year book of business as a result of the uncertainty of the pandemic. And, you know, I think as you look at the combination of the companies, Greg, there's about $20 million of expense synergies. And we will proceed with a very consistent underwriting model and strategy when we combine the companies together. And I think the other thing to keep in mind on the transaction, just from a strategic standpoint, is we're combining our roughly $250 million of standard physician business with theirs. And that's been the more profitable segment of the market. Theirs represents roughly 250 to 275 million. And as we put them together, we will certainly take advantage of the geographic diversification and all the expense synergies and, you know, combine our underwriting strategies. And I'll just say there, it's been a more profitable piece of the MPL business over the cycle. And they also have a smaller specialty book of business relative to ours. So, you know, the game plan is to integrate, build an attractive national platform with scale on a regional basis and continue to work hard to bring the organizations together to produce a profit for shareholders.
spk09: So just one follow-up on the NorCal. If I look at your specialty PC business, and you guys provide a detail around why the top line's moving down, is it fair to assume that their top line, their gross premium written, and their net written premium on a year-to-date basis is also down between 5% and 10% like yours?
spk01: Greg, I'd have to check. notes on that. But for sure in specialty, I think the standard physician book has been much more stable for them.
spk09: Got it. All right.
spk03: And I think important to that is the specialty book at NorCal is very small. I mean, it is 90 plus percent just physician business. So it doesn't have the impact that it would have like it does on our book.
spk09: So let's, let's just be clear. You said it's running around 120%, um, percent combined ratio year to date. That's their total business, correct? That's correct. Okay. Um, uh, I want to, I mean, I have a capital question before I get to that. I just, um, net investment income. Um, so just look at the consolidated numbers, you know, and I know you provided some detail on why certain things are down, but. on a year-to-date basis is down 20%, down 28.5% just from page one of your press release in the third quarter. I understand there's a lot of moving pieces with the volatile markets, et cetera. But when we're sitting here on the outside looking in and what kind of guideposts can you put around our investment income assumptions. And let's keep NorCal aside. When we think about 2021 and 2022, is it, you know, is it going to stabilize at this new run rate? Is it going to go up? Can you help us, you know, put something together there?
spk03: Dana, do you want to respond to that?
spk00: Yes. Yeah, I'd be happy to, Ned. Yeah, Greg, it's a good question. So when you're looking at our current quarter results, let's say, or on a year-to-date basis, and you're comparing that to the prior year, probably one of the most significant factors that are impacting those numbers is the fact that since that time, over the course of, say, the second half of 2019 and early in 2020, we were de-risking our investment portfolio. So you're seeing the results now of a lower allocation, the impact of a lower allocation to our equity investments. And of course, additionally, you're seeing the impact of just the lower yields overall in the remainder of the portfolio. So as you look sort of, I think that what we've got here in the current quarter is a good basis for go forward.
spk09: So, so just to clarify, you know, I'm, I'm looking at your total portfolio, you know, of 3.3, 3, 3.3, 6, 6 billion. You're, you're saying the, the, the, the, on a consolidated basis, 55, $56 million quarterly number off that asset base is sort of a good run rate to assume going forward. Again, X NorCal, because obviously when you bring NorCal on, it's going to be an adjustment.
spk00: Yeah, so in the current quarter, we're at about $16 million. Yeah, so in that 60 range is where you can sort of start off of that consolidated view of our net investment income and go forward from there because we're not reallocating at this point, any portion of the portfolio significantly. Got it.
spk03: Yeah. I would keep in mind there, Greg, that we were probably reinvesting at lower rates than what's maturing off the portfolio, given where rates are right now. Right.
spk09: I, but I, I mean, you've done, thank you very much for that. It, that, that does help us, you know, sort of set expectations at least on a, you know, as we think about next year. Right. I guess the final question, and I'm sure there's others that may ask questions, would be just around capital. I, I, you know, uh, the goodwill charge obviously doesn't necessarily affect capital, but it does, you know, your book value per share did take a hit. So where, where do you think the company is in terms of excess capital today? And I guess more important, you know, once NorCal is done, where do you think the company will be on a pro forma basis in terms of excess capital once on the close of NorCal?
spk03: Great. So that's a good question. Um, You know, one of the challenges I think of the environment that we are in right now and all the uncertainty that comes along with it is a need and a desire to hold more capital and be more conservative in your capital base. So, you know, I think that leads what we think from kind of a liquidity standpoint. that's really where we're focused in funding for the NorCal transaction, and we've got, I think, a very solid plan on how we're going to approach that and what we think will close in the first quarter of next year. The transaction with NorCal is a book value transaction the way it's structured, and so it doesn't erode any capital in the organization, and it allows us on an operational basis to operate at a slightly higher leverage ratio, but one that we think is very sustainable for the organization. And so I'm not sure if that's entirely responsive to your question, but that's kind of our view of things.
spk09: And well, it isn't really, but I understand that you, I understand parts of it and, I'll take the rest offline. Thank you for your answers.
spk05: And our next question will come from Mark Hughes with Truist. Please go ahead. Thank you.
spk02: Good morning. When we think about the fourth quarter, you're through with your re-underwriting program. You've been putting rate increases in place. This quarter, your specialty P&C written premium is down kind of mid-single digits. Is there an inflection point in the fourth quarter? I know you don't provide guidance, but I'm just trying to think about, you know, now that you're through, just as you say, a lot of these steps, what is the profile of the business? I'm thinking more specialty P&C. How does that look in the fourth quarter and in the next year?
spk03: Maybe I'll take kind of the inflection point question, then I'll let Mike talk more specifically about the specialty book. You know, because we write a very long-tailed line of business and compounded by the uncertainty that the pandemic brings, if there is an inflection point that's going to come, it's not going to come in the fourth quarter. It's somewhere down the road. um, when we have greater clarity about the ultimate impacts of the pandemic and the ultimate impacts of all the measures that we've taken. We're very positive and very bullish on, on everything we're doing, but it's going to take time for the confidence, um, to come through, especially in the actuarial analysis of those measures. And we're going to be cautious.
spk02: Yeah.
spk03: And if I might, uh,
spk02: I was thinking a little more top line. I'm completely with you on the visibility around your question.
spk03: Yeah, so Mike can talk more about the kind of inflection point on the top line or lack thereof. So, Mike, why don't you handle that?
spk01: Sure, Ned. Good morning, Mark. Just to kind of look at the overall specialty P&C segment. We're kind of seeing at our medical technology business relatively flat trends, but some pretty good new business opportunities as a result of the pandemic and certainly our excess product. In our small business unit IST, which is roughly $100 million book, we're kind of looking at that. And we're seeing strong retentions, some rate starting to come through the book, and hopeful to see that grow a little bit more on the new business side, both in the fourth quarter and then as we move forward out into 2021. I think in healthcare professional liability, when you look at the top line, specialty has been re-underwritten pretty aggressively over the last year, as you can tell by the retentions over the last several quarters. We're substantially through that. We do have, Mark, some two-year policies that were written in 2019 that will come up, you know, kind of in the first quarter that are larger that could provide us with potential volatility. But I will say this, that, you know, we're substantially through that process, and we're expecting retentions to stabilize throughout 2021 in the specialty area. In the standard physician business, again, we are pleased with the 85% retention this quarter. We still expect there's a lot of competition in that market. I think the specialty market certainly has firmed much more, and we have the ability to achieve additional rate product structure terms and condition improvement. But we still see, particularly on a state-by-state basis, the standard physician market being pretty competitive. So we're keeping an eye on that as far as retention rates going forward. But as far as the major components of the re-underwriting effort, we've really been through them as we proceed into the fourth quarter. Like I said, with a couple of larger accounts in 2021 in specialty that could provide some volatility.
spk02: Thank you for that. The impairment, Dan, I think you suggested didn't impact the workers' comp business. If it's a function of kind of the broader stock price, what's the distinction between the older MedMal acquisitions versus the workers' comp acquisitions?
spk03: Hey, I think it's really where the volatility in our business has been that is the distinction. So when you look at the volatility of our operating results, they're emanating from the specialty P&C side of things. And the results in the work comp side have been much more stable.
spk02: Ned, you mentioned Lloyd's outlook for the losses from the recent weather. you say the it's within expectations does that say it still will be a tough quarter um uh you know not uh out of line with bad quarters in the past but still a tougher quarter yeah so yeah i think it will be a tough quarter um we're still gathering data um and and you know as as as always with the with the storms and other
spk03: cat events, it takes a little while before you have the kind of totality of things. We said we kind of expect it within our expected cat load, but it certainly will put some pressure on the quarter. I don't know, Dana, if we've got any more insight since we've got the quarter lag, if we've got any more insight at this point into what we think that might look like.
spk00: No, I think you've accurately reflected what we know at this point.
spk03: I think we're likely to post a loss for the quarter, but not a tremendously sizable loss, something under a couple million dollars.
spk08: Okay, understood. Thank you. And once again, if you'd like to ask a question, please press star then 1. Our next question will come from Paul Newsom with Piper Sandler. Please go ahead.
spk07: Sorry, you hit most of my questions, but I'd like to beat the Lloyd's thing just a little bit longer, just so I know. So the impact of the reduced participation, that's because of the lag isn't going to happen. This isn't going to be reported next quarter. It'll be in the first quarter, right? Is that the way I got it right?
spk03: So a couple of things there, Paul, just to make sure. Sorry if we weren't clear. The The reduced participation on Syndicate 6131, which is a small special purpose syndicate that we participate in, that reinsurance was effective July 1, so it'll be in our fourth quarter, their third quarter. The reduced participation in the Syndicate 1729 started in the first quarter of this year for them and so had been our second quarter, but recognized that Because a lot of the business they write is reinsurance that earns out over 24 months as opposed to 12 months, that it doesn't manifest itself quite as quickly as it would if everything were just earning out over 12 months.
spk07: Okay. I think I got that. I apologize. It's not you. I'm sure it's me that confused you. No, I'm sure it's me, Paul. Thanks. Okay. And then any sort of broader thoughts on the competitive environment in the specialty business? Obviously, you've talked about it a little bit already, but I guess I'm a little bit surprised to see comments about continued competition. And I guess is that because other folks are not seeing the results that you are, or is it some other things that you think may be going on in the competitive environment?
spk03: I'll let Mike respond initially to that. Mike, do you want to talk about what you guys are seeing in the specialty P&C market?
spk01: Yeah. Thanks, Ned. And good morning, Paul. Just a couple observations. It has clearly been more competitive in the standard physician's market, but it's state by state. In the more challenging venues, and as you can see with our results through the third quarter with double-digit rate increases, there are areas where the standard physician market is firming up, and that's more of a state-by-state basis. There are some other states that are highly, highly competitive, and you're not able to achieve the rate objectives and secure as much new business if you want in those targeted states. The specialty, which includes, you know, just the hospital market, you know, senior care market, has been pretty firm all year. I mean, we've been really pleased both on new business and the renewal terms that we've been able to secure in that market has been really helpful to turn that book around. And I'm, you know, talking about, you know, The rates, the product structure changes, terms, conditions, reduced limits, all those add up to a much more profitable book on the renewals that we've handled and the selective new business that we've written there. And then the other thing that I would say just in general is new business opportunities have definitely been – down a bit across the HCPL market as a result of the disruptions from COVID-19 as far as submission activity. So we're hoping that will pick up as we go through the fourth quarter and into 2021. We did see some nice cadence in new business in the fourth quarter, and we're hoping that continues. We wrote $8.7 million in just slightly less than the 2019 quarter of nine. So we're hopeful to have a more consistent new business year in 2020 as some of the issues with the pandemic hopefully reside, you know, just kind of get a little bit more easier for us to deal with in the marketplace.
spk03: And I just want to clarify, Mike, I think you said fourth quarter for that $8.7 million. That was our third quarter new business number.
spk06: Yeah, thank you, Ned. Great, thank you. And I think I heard someone knock on wood about improved situations, so I'm going to do the same. Appreciate it.
spk08: And our next question is a follow-up from Mark Hughes with Truist. Please go ahead.
spk02: Yeah, thank you. I think you might have touched on this, but as you look at how older claims are developing in the current environment, clearly new claims are down. So I'm curious whether the current circumstances have affected your ability to close the claims, any maybe administrative disruptions, anything like that, or alternatively, whether there's been more motivation to close claims and to cease Interested to hear you talk about what's going on in the back book, so to speak.
spk03: Yeah, Mark, thanks. And I'll let Mike chime in as well. But, you know, one of the bigger issues is, especially early on in the pandemic, is that the court systems largely shut down. And as an organization that goes to bat for its insureds, not having the courts open for those trials certainly has slowed things down on that end. And then I think it's probably a mixed bag on what the ultimate impact of that is. I think for some people it is probably driving towards settlement sooner, and for others they're happy to ride out kind of the administrative delays. We are beginning to see the court systems open up some, you know, maybe not fully, but in certain jurisdictions they are working toward trials and certainly things like depositions and other things parts of the process have opened back up much more significantly. All right, so I got some statistics from Rob Francis. We have only had four trials since February. Over that same timeframe last year, we had 74 trials. So that gives you a sense of what's going on with the court system. Mike, I'm not sure what you might add to that.
spk01: No, Ned, I don't have anything additional to add.
spk02: So four trials since February. I mean, and this may be too narrow a gauge to be relevant, but your favorable development was a little lower this quarter. Is it just not possible to get resolution, and so therefore the reserves are kind of frozen in place if you're only talking about four trials versus three? 74 last year.
spk03: That's a pretty big difference. We talked about the uncertainty that comes in that COVID brings, and this is one of those areas. And so it is, as I said, it's a mixed bag on kind of the impacts having on closures. I think it is slowing down claim closures. And, you know, what the actuaries hate more than anything is inconsistency and data, right? And so when you have these disruptions and it becomes a greater challenge to analyze. And I think when that happens, you approach that with a lot of caution as to what it means, which is what we're doing.
spk02: And I had one other question, and again, a lot of this has been touched on, but if I was just doing kind of the simple approach of the trend in pricing versus the trend in losses, kind of loss costs, inflation versus pricing trends, how would you characterize it in the healthcare professional liability space?
spk01: Mike, do you want to take that? Yeah, I will. Just from a standpoint of frequency, it's been relatively flat except for this COVID impact that we've been talking about. On the severity trend, it's it's so, there's such a variation by state. We have some states that have, you know, pretty benign severity trends. There's others that are high single digit, but, you know, just kind of, what we're tending to see is severity trend in that kind of three to three and a half to four percent range, you know, depending on the state. And then obviously we're taking our our rate actions off of that kind of trend as we move forward. We are getting nice margin over our lost cost trends as we look out throughout 2020 for sure. And I guess the other thing that I'd say is just you can see that in the kind of accident year loss ratio reduction since the year end 2019. It's roughly six and a half points exclusive of COVID and exclusive of the large national healthcare tail. So we're seeing some positive trends.
spk02: And again, the six and a half points, and I'm sorry if I missed that point, but that number is if you exclude COVID, if you exclude the large national accounts within the specialty PNC, the improvement of 6.5 points?
spk01: Yeah, that's a number relative to year-end 2019, and it's an action-at-year number.
spk02: Yeah, okay. And then, Dana, the income from the equity in unconsolidated subsidiaries is It was $5 million this quarter. I think it was much more of a downdraft last quarter. Do you have any early view on how that's going to shake out in the fourth quarter? I think that's another one that's on a one-quarter lag. Do we have visibility for that?
spk00: So within the equity and earnings, those LPs and LLCs tend to follow the broader equity markets. It's just that we were reporting them on a quarter lag, so that's how you see it come through our financial statement. So that's probably the best guidance that I can give you around equity and earnings.
spk02: Yeah, yeah. Okay. All right.
spk08: Thank you very much.
spk05: And again, if you'd like to ask a question, please press star then more. And this will conclude our question and answer session.
spk08: Would the company like to make any closing remarks?
spk10: No, thank you, Cole. I just want to thank everybody that joined us today. And, again, please stay safe and healthy, and we look forward to speaking with you again in February.
spk08: The conference is now concluded. Thank you for attending today's presentation. You may now disconnect your lines at this time and have a great day.
Disclaimer